RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
靶向免疫细胞的纳米制剂用于癌症治疗：mRNA 疗法
英文原题：Nanoformulations targeting immune cells for cancer therapy: mRNA therapeutics.
查看英文原题
Nanoformulations targeting immune cells for cancer therapy: mRNA therapeutics.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
2020年底，两种信使RNA（mRNA）疫苗（BNT162b2和mRNA-1273）在全球范围内获批使用，这证明了mRNA疗法与脂质纳米制剂技术在COVID-19大流行期间保护人们免受冠状病毒感染方面取得了显著成功。这种前所未有的、令人兴奋的纳米制剂与mRNA疗法双管齐下的策略，被认为在未来靶向癌症免疫治疗中是一种有前景的范式。近年来纳米制剂技术的进展在将mRNA平台应用于癌症治疗方面发挥了重要作用。在这篇综述中，我们介绍了mRNA技术的生物学原理和进展，以及引人注目的mRNA递送纳米制剂的化学基础。
我们讨论了最新的有前景的纳米mRNA疗法，通过调节靶向特定亚型的免疫细胞来增强癌症免疫治疗，例如在外周淋巴器官中的树突状细胞（DCs）以启动mRNA癌症疫苗介导的抗原特异性免疫治疗，以及在肿瘤微环境（TME）中的DCs、自然杀伤（NK）细胞、细胞毒性T细胞或多种免疫抑制性免疫细胞以逆转免疫逃逸。
我们重点介绍了先进纳米mRNA疗法在靶向癌症治疗中的临床进展，并就这一变革性整合技术走向临床实施的未来方向提供了我们的观点。
展开英文摘要原文
The approved worldwide use of two messenger RNA (mRNA) vaccines (BNT162b2 and mRNA-1273) in late 2020 has proven the remarkable success of mRNA therapeutics together with lipid nanoformulation technology in protecting people against coronaviruses during COVID-19 pandemic. This unprecedented and exciting dual strategy with nanoformulations and mRNA therapeutics in play is believed to be a promising paradigm in targeted cancer immunotherapy in future.
Recent advances in nanoformulation technologies play a prominent role in adapting mRNA platform in cancer treatment. In this review, we introduce the biologic principles and advancements of mRNA technology, and chemistry fundamentals of intriguing mRNA delivery nanoformulations.
We discuss the latest promising nano-mRNA therapeutics for enhanced cancer immunotherapy by modulation of targeted specific subtypes of immune cells, such as dendritic cells (DCs) at peripheral lymphoid organs for initiating mRNA cancer vaccine-mediated antigen specific immunotherapy, and DCs, natural killer (NK) cells, cytotoxic T cells, or multiple immunosuppressive immune cells at tumor microenvironment (TME) for reversing immune evasion.
We highlight the clinical progress of advanced nano-mRNA therapeutics in targeted cancer therapy and provide our perspectives on future directions of this transformative integrated technology toward clinical implementation.
论文信息
- 作者
- Yang W、Cao J、Cheng H、Chen L、Yu M、Chen Y、Cui X
- 单位
- Department of Urology, Xinhua Hospital, School of Medicine, Shanghai Jiaotong University, 1665 Kongjiang Road, Shanghai, 200092, PR China.China
- 期刊
- Bioactive materials2023 May
- 原文标识
- PubMed 36471724 · DOI 10.1016/j.bioactmat.2022.11.014
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →